Bioconjugated Nanomaterial for Targeted Diagnosis of SARS-CoV-2

Acc Mater Res. 2022 Jan 12;3(2):134-148. doi: 10.1021/accountsmr.1c00177. eCollection 2022 Feb 25.

Abstract

Infectious diseases by pathogenic microorganisms are one of the leading causes of mortality worldwide. Healthcare and socio-economic development have been seriously affected for different civilizations because of bacterial and viral infections. According to the Centers for Disease Control and Prevention (CDC), pandemic in 1918 by the Influenza A virus of the H1N1 subtype was responsible for 50 to 100 million deaths worldwide. Similarly, the Asian flu pandemic in 1957, Hong Kong flu in 1968, and H1N1pdm09 flu pandemic in 2009 were responsible for more than 1 million deaths across the globe each time. As per the World Health Organization (WHO), the current pandemic by coronavirus disease 2019 (COVID-19) due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is responsible for more than 4.8 M death worldwide until now. Since the gold standard polymerase chain reaction (PCR) test is more time-consuming, the health care system cannot test all symptomatic and asymptomatic Covid patients every day, which is extremely important to tackle the outbreak. One of the significant challenges during the current pandemic is developing mass testing tools, which is critical to control the virus spread in the community. Therefore, it is highly desirable to develop advanced material-based approaches that can provide a rapid and accurate diagnosis of COVID-19, which will have the capability to save millions of human lives. Aiming for the targeted diagnosis of deadly virus, researchers have developed nanomaterials with various sizes, shapes, and dimensions. These nanomaterials have been used to identify biomolecules via unique optical, electrical, magnetic, structural, and functional properties, which are lacking in other materials. Despite significant progress, nanomaterial-based diagnosis of biomolecules is still facing several obstacles due to low targeting efficiency and nonspecific interactions. To overcome these problems, the bioconjugated nanoparticle has been designed via surface coating with polyethylene glycol (PEG) and then conjugated with antibodies, DNA, RNA, or peptide aptamers. Therefore, the current Account summarizes an overview of the recent advances in the design of bioconjugated nanomaterial-based approached as effective diagnosis of the SARS-CoV-2 virus and the SARS-CoV-2 viral RNA, antigen, or antibody, with a particular focus on our work and other's work related to this subject. First, we present how to tailor the surface functionalities of nanomaterials to achieve bioconjugated material for targeted diagnosis of the virus. Then we review the very recent advances in the design of antibody/aptamer/peptide conjugated nanostructure, which represent a powerful platform for naked-eye colorimetric detection via plasmonic nanoparticles. We then discuss nanomaterial-based surface-enhanced Raman scattering (SERS) spectroscopy, which has the capability for very low-level fingerprint identification of virus, antigen, and antibody via graphene, plasmonic nanoparticle, and heterostructure material. After that, we summarized about fluorescence and nanoparticle surface energy transfer (NSET)-based on specific identification of SARS-CoV-2 infections via CNT, quantum dots (QDs), and plasmonic nanoparticles. Finally, we highlight the merit and significant challenges of nanostructure-based tools in infectious diseases diagnosis. For the researchers who want to engage in the new development of bioconjugated material for our survival from the current and future pandemics, we hope that this Account will be helpful for generating ideas that are scientifically stimulating and practically challenging.